Replies to post #736393 on NorthWest Biotherapeutics Inc (NWBO)

[dstock07734]

You and your ilk have the same pattern: cheery pick and twist truth.

I got something straight for you. Do you know what the following is about? By now, you should know since I have been posting a lot about the variations of genes pre- and post- treatment. This is the data from the neoadjuvant therapy of keytruda on rGBM patients and the trial was running along the same time the combo trial was undergoing. BTW, Merck is the collaborator of this trial too. Here they only posted the data from the post-treatment. No doubt the data of this type should be collected from the combo trial. Can you imagine what would happen to the C-suite of Merck if the comparison of the data were presented to them?

BTW, the trial has the end of next January as completion date. What did 10Q say about the end of next January? It could be coincidental. But in biotech, no coincidence.

Buckle up and get ready for the final checkmate.

[survivor1x]

Actually according to Linda Liau. The Mesenchymal's are performing relatively the best. and the Mesenchymal's ARE the "sickest" ones if you want to call them that. This was directly from LL herself minute 17ish

Tell me how patients with the worst prognosis end up performing the best - I will tell you (DCVAX).